A carregar...
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
Resistance to targeted therapy is an ongoing problem for the successful treatment of Stage IV metastatic melanoma. For many patients, the use of targeted therapies, such as BRAF kinase inhibitors, were initially promising yet resistance inevitably occurred. Even after combining BRAF kinase inhibitor...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650456/ https://ncbi.nlm.nih.gov/pubmed/29088901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18523 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|